BioNTech SE (NASDAQ: BNTX) reported Q1 EPS of EUR14.24. Revenue for the quarter came in at EUR6.4 billion.

The company reiterated COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billion.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.